DCN Dx completed the acquisition of Biomed Diagnostics.

DCN Dx, a company in the end-to-end development, manufacture, and commercialization of point-of-use tests, completed the acquisition of Biomed Diagnostics, a microbiological testing products company. Financial terms were not disclosed. "Biomed has a strong presence in microbiological testing for veterinary, human, food safety and environmental markets, and has developed innovative solutions that combine specimen collection, culture and transport in a single device. The portfolio of novel testing and sampling products is a perfect adjacency for DCN Dx's core business of point-of-use test development. We're excited to integrate Biomed's capabilities into our own as we provide world-class solutions to our clients," Charlie Mamrak, DCN Dx CEO.